期刊文献+

小剂量紫杉醇联合顺铂周疗方案在Ⅰb2~Ⅱb期宫颈癌新辅助化疗中的应用 被引量:29

下载PDF
导出
摘要 目的探讨小剂量紫杉醇联合顺铂周疗方案在Ⅰb2~Ⅱb期宫颈癌新辅助化疗中的应用价值。方法60例Ⅰb2~Ⅱb期宫颈癌患者随机分为TP1组32例和TP2组28例。TP1组采用小剂量紫杉醇联合顺铂周疗方案治疗:紫杉醇60 mg/m2、顺铂20 mg/m2静滴,8~10 d后重复一疗程。TP2组采用传统紫杉醇联合顺铂3周方案治疗:紫杉醇135 mg/m2,、顺铂60 mg/m2静滴,3周1个疗程。2~3个疗程后评估疗效,并行宫颈癌根治术,术后根据石蜡病理补充放化疗。结果两组因化疗效果差改行根治性放疗者2例,化疗总有效率为96.6%。TP1组平均术前等待时间为28.2 d,少于TP2组的58.1 d(P<0.05)。TP1组术后12例(40%)行放化疗,TP2组10例(35.7%)(P>0.05)。两组均无治疗相关性死亡。TP1组2例出现Ⅲ度及以上骨髓抑制者,TP2组为11例(P<0.05)。结论小剂量紫杉醇联合顺铂周疗方案用于Ⅰb2~Ⅱb期宫颈癌新辅助化疗效果肯定,且不良反应较小。
机构地区 新乡市中心医院
出处 《山东医药》 CAS 2012年第30期39-40,共2页 Shandong Medical Journal
  • 相关文献

参考文献9

  • 1Chen XS, Nie XQ, Chen CM, et al. Weekly paclitaxel plus carbo- platin is an effective nonanthraeyeline -containing regimen as neo- adjuvant chemotherapy for brease cancer[ J]. Ann Oncol, 2010,21 (5) :961-967.
  • 2Yeo KO, Hyun JL, Mi-Hee J, et al. Role of activating transcrip- tion factor 3 on tap73 stability and apoptosis in paclitaxel treated cervical cancer cells [ J ]. Molecular Cancer Research, 2008,6 (7) :1232-1249.
  • 3Kuh HJ, Jang SH, Wientjes MG, et al. Computational model of intracellular pharmacokinetics of paclitaxel [ J ]. J Pharmacol Exp Ther, 2000,293(3) :761-770.
  • 4陆红霞,徐丛剑,李斌.紫杉醇剂型、临床用药方式及联合用药的研究进展[J].国外医学(药学分册),2005,32(2):73-77. 被引量:11
  • 5Mori T, Kinoshita Y, Watanabe A, et al. Retention of paclitaxel in cancer ceils for 1 week in vivo and in vitro [ J ]. Cancer Che- mother Pharmacol, 2006,58 (5) :665-672.
  • 6程萌,谢聪,王丹青,尹如铁,康德英.紫杉醇治疗上皮性卵巢癌密集型疗法的系统评价[J].中国循证医学杂志,2009,9(12):1328-1335. 被引量:1
  • 7Sehouli J, Stengel D, Mustea A. Weekly paclitaxel and carboplatin for patients with primary advanced ovarian cancer: results of a mul- ticenter phase-II study of the NOGGO [ J ]. Cancer Chemother Pharmaeol, 2008,61 (2) :243-250.
  • 8Gianni L, Kearns CM, Gianni A, et al. Nonlinear pharmaeokinet- ies and metabolism of paclitaxel and its pharmaeokinetic/ pharma- eodynamie relationships in humans[J]. J Clin Oneol, 1995, 13 ( 1 ) : 180-190.
  • 9Moil T, Hosokawa K, Kinoshita Y, et al. Neoasjuvant chemother- apy with weekly earboplatin and paelitaxel for locally advanced cer- vical carcinoma[ J]. Int J Gynecol Cancer, 2008, 18 ( 1 ) :85-89.

二级参考文献30

  • 1陆红霞,徐丛剑,李斌.紫杉醇剂型、临床用药方式及联合用药的研究进展[J].国外医学(药学分册),2005,32(2):73-77. 被引量:11
  • 2沈铿,李孟达,丰有吉,马丁,李子庭,谢辛,孔北华,崔恒,宋垒,彭芝兰,李力,吴鸣,陈亦乐,刘继红,吴令英,郎景和,中国妇科肿瘤学组.泰素周疗和三周疗法作为卵巢癌一线化疗的多中心对照研究[J].中华医学杂志,2005,85(30):2099-2103. 被引量:16
  • 3段微,路虹,范逢晓.国产紫杉醇治疗上皮性卵巢癌周疗方案与月疗方案的比较[J].中国肿瘤临床与康复,2006,13(1):73-74. 被引量:2
  • 4Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer, 2000, 88(11): 2619-2628.
  • 5Kuh HJ, Jang SH, Wientjes MG, et al. Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther, 2000, 293(3): 761-770.
  • 6Mori T, Kinoshita Y, Watanabe A, et al. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol, 2006, 58(5): 665-672.
  • 7Choy H, Akerley W, Safran H, et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small- cell lung cancer.J Clin Oncol, 1994, 12( 12): 2682-2686.
  • 8Sehouli J, Stengel D, Mustea A, et al. Weekly paclitaxel and carboplatin (PC-W) for patients with primary- advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol, 2008, 61 (2): 243-250.
  • 9Higgins JLT, Green S. The Cochrane collaboration. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. The Cochrane Library, 2006.
  • 10Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premeditation to patients with ovarian cancer previously treated with platinum. Acta Oncol, 2002, 41(5): 418- 424.

共引文献10

同被引文献243

引证文献29

二级引证文献188

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部